(Reuters) – Gilead Sciences Inc GILD.O will acquire biopharmaceutical company Immunomedics Inc IMMU.O for $21 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the companies said on Sunday in a statement.

Continue Reading Below

Gilead will buy Immunomedics for $88 per share in cash, according to the statement.

Source Link:
https://www.foxbusiness.com/markets/gilead-to-buy-immunomedics-in-21b-deal

[]

Comments

comments

Advertisement